Agennix gets EUR 15 million loan

Agennix AG (Xetra:AGX) received an unsecured EUR 15 million ($19.4 million) loan from existing investor dievini Hopp BioTech. The loan bears 6% interest.

Agennix's talactoferrin is in Phase III testing to treat non-small cell lung cancer (NSCLC) and has completed a Phase II trial to treat sepsis. Agennix said it plans to raise additional funds this year to complete the Phase III trial, with top-line data expected late 2011. Talactoferrin is a recombinant human lactoferrin (rhLF) dendritic cell recruiter and activator (DCRA) immunomodulatory protein. ...